Search

Your search keyword '"Altomonte, Jennifer"' showing total 222 results

Search Constraints

Start Over You searched for: Author "Altomonte, Jennifer" Remove constraint Author: "Altomonte, Jennifer"
222 results on '"Altomonte, Jennifer"'

Search Results

3. Development of a dendritic cell vaccine against HCC using the immunogenic oncolytic virus VSV-NDV

6. A Novel Chimeric Oncolytic Virus Mediates a Multifaceted Cellular Immune Response in a Syngeneic B16 Melanoma Model.

7. Author Correction: Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC

8. Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC

10. Supplementary Fig. S1 from Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib

11. Supplementary tables S1-3 and figure legends from Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib

12. Klinische und therapeutische Relevanz von viralen Onkogenen bei sinunasalen Plattenepithelkarzinomen.

13. Process intensification strategies toward cell culture‐based high‐yield production of a fusogenic oncolytic virus.

16. Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies

17. Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma

18. Hyperpolarized ¹³C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC

19. Author Correction: Hyperpolarized ¹³C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC

20. Oncolytic Virotherapy with the Fusogenic VSV-NDV Platform Complementing Adoptive T Cell Therapy

23. Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC

24. PPAR[alpha] mediates the hypolipidemic action of fibrates by antagonizing FoxO1

25. Evaluation of hepatitis B virus surface protein variations in patients under therapy with nucleic acid polymer REP 2139-Ca

26. Evaluation of hepatitis B virus surface protein variations in patients under therapy with nucleic acid polymer REP 2139-Ca

28. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice

39. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma

43. Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses

47. Optimization of Oncolytic Viral Therapy for Hepatocellular Carcinoma

48. Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib

Catalog

Books, media, physical & digital resources